Moderna

MRNA on Nasdaq. Moderna sells COVID and RSV vaccines to governments, pharmacies and patients. Market value $90.4bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-2.4%low

For every $100 of what the whole company costs, it produced $-2.44 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 58 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$199.33 a share, 795% above its 1-year low

Over the past year the price has ranged from $22.28 to $280.80.

Pays no dividend

Price from Thursday’s close (19 November).

Five years of cash, in billions

13.3
4.6
-3.8
-4.1
-2.1
-2.0
2021202220232024202512 monthsto Sep '26
Revenue
$18.5bn$19.3bn$6.8bn$3.2bn$1.9bn
Operating margin
72.0%48.9%-61.9%-121.9%-158.1%
Debt to equity
n/an/an/a0.010.07
Shares outstanding
0.38bn0.38bn0.38bn0.39bn0.40bn

Health checks

  • Free cash flow positive2 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.07× equity
  • Revenue growth, five yearsStrong, 19.3% a year
  • Buying back its own sharesNo, 5% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.3 billion last quarter, up 29% on a year ago.
  • Profit: $162 million, after a loss of $200 million a year ago.
  • It loses 116 cents on each $1 of sales, compared with 155 cents a year earlier.
  • Over the past 12 months it spent $2 billion more cash than it brought in, compared with $2.7 billion a year earlier.
  • 10% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in 3 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$966m
March 2025$108m
June 2025$142m
September 2025$1.0bn
December 2025$678m
March 2026$389m
June 2026$145m
September 2026$1.3bn
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$1.1bn
March 2025-$971m
June 2025-$825m
September 2025-$200m
December 2025-$826m
March 2026-$1.3bn
June 2026-$782m
September 2026$162m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
12 February 2027
Last annual report (10-K)
20 February 2026
Next quarterly (estimated, 10-Q)
5 February 2027

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 781 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 6 sold $99m, $97m of it under preset trading plans.

  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    17 November 2026
    Shares
    39,215
    Price
    $211.61
    Value
    $8m
  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    16 November 2026
    Shares
    39,160
    Price
    $219.66
    Value
    $9m
  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    15 October 2026
    Shares
    39,145
    Price
    $220.72
    Value
    $9m
  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    14 October 2026
    Shares
    39,224
    Price
    $213.48
    Value
    $8m
  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    15 September 2026
    Shares
    40,281
    Price
    $146.07
    Value
    $6m
  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    14 September 2026
    Shares
    40,294
    Price
    $144.13
    Value
    $6m
  • Mock James M
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    34,836
    Price
    $134.49
    Value
    $5m
  • Klinger Shannon Thyme
    Chief Legal Officer
    Sold
    under a preset trading plan
    Date
    1 September 2026
    Shares
    3,471
    Price
    $139.95
    Value
    $485,766
  • Bancel Stephane
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    5 August 2026
    Shares
    499,246
    Price
    $57.52
    Value
    $29m
  • Hoge Stephen
    President
    Sold
    under a preset trading plan
    Date
    15 July 2026
    Shares
    53,336
    Price
    $67.60
    Value
    $4m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 20 Feb 2026, plus the 10-Q filed 6 Nov 2026 and 8 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.